ENDRA Life Sciences Inc. — Director's Dealing 2019

Dec 11, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2019-12-11

Reporting Person: Thornton Michael Milos (Chief Technology Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-12-11	Stock option (right to buy)	$0.90	A	575906	Acquired	2029-12-11	Common Stock (575906)	Direct
2019-12-11	Series A Convertible Preferred Stock	$0.87	A	43.719	Acquired		Common Stock (50252)	Direct
2019-12-11	Warrants	$0.87	A	50252	Acquired	2024-12-11	Common Stock (50252)	Direct

Footnotes

F1: These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date.

F2: The Series A preferred stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A preferred stock is convertible into common stock at a price per share of $0.87.

F3: The Series A preferred stock has no expiration date.

F4: The Warrants were issued for no additional consideration in connection with the purchase of the Series A preferred stock.